Lyra Therapeutics Inc (LYRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 09-2020 | 06-2020 | 03-2020 | 12-2019 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 74,593 | 81,555 | 86,599 | 35,247 | 9,808 |
| TOTAL | $75,917 | $83,555 | $89,310 | $35,540 | $10,119 |
| Non-Current Assets | |||||
| PPE Net | 2,165 | 917 | 329 | 284 | 237 |
| Other Non-Current Assets | 2,748 | 2,858 | 3,084 | 4,942 | 4,607 |
| TOTAL | $4,913 | $3,775 | $3,413 | $5,226 | $4,844 |
| Total Assets | $80,830 | $87,330 | $92,723 | $40,766 | $14,963 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 922 | 530 | 1,146 | 1,358 | 1,069 |
| Accrued Expenses | 2,977 | 3,214 | 1,853 | 2,881 | 3,240 |
| TOTAL | $4,884 | $4,708 | $3,942 | $5,158 | $5,208 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 1,454 | 1,708 | 1,958 | 2,192 | 2,427 |
| TOTAL | $1,454 | $1,708 | $1,958 | $2,192 | $2,427 |
| Total Liabilities | $6,338 | $6,416 | $5,900 | $7,350 | $7,635 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 259 | 259 | 258 | 258 | N/A |
| Common Shares | 13 | 13 | 13 | N/A | N/A |
| Retained earnings | -149,884 | -142,863 | -136,529 | -131,989 | -127,757 |
| Other shareholders' equity | 0 | 0 | 0 | 160,197 | 130,666 |
| TOTAL | $74,492 | $80,914 | $86,823 | $33,416 | $7,328 |
| Total Liabilities And Equity | $80,830 | $87,330 | $92,723 | $40,766 | $14,963 |